Cancer Ear, Nose and Throat Ototoxicity, Solid Cancers
Conditions
Interventions
Dexamethasone
Nothing
Sponsors
COLLEGE OF MEDICINE
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with solid cancers on cisplatin based chemotherapy
Exclusion criteria
Exclusion criteria: 1. Severely ill patients who cannot undergo the hearing examination. 2. Pathological findings on otoscopy that do not allow safe ITD delivery 3. Previous inner ear disease with resultant sensorineural hearing loss 4. Conductive hearing loss >5 dBHL 5. Pure tone thresholds average (PTA) >40 dBHL for the frequencies 500 to 3000 Hz or 4000 to 8000 Hz16 6. Asymmetry of PTA between the ears >10 dBHL for the frequencies 500 to 3000 Hz or 4000 to 8000 Hz16 7. Previous treatment with Cisplatin 8. History of radiation therapy (or planned concurrent radiation therapy) to the head and neck regions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pure tone audiometry result | — |
Secondary
| Measure | Time frame |
|---|---|
| Pattern of hearing loss secondary to Cisplatin ototoxicity | — |
Countries
Nigeria
Contacts
Public ContactAYORINDE FOLASIRE
LECTURER/RADIATION ONCOLOGIST
Outcome results
None listed